Photo: Closeup of microscope


Siponimod (also known as BAF312 or Mayzent) is a tablet being developed for secondary progressive MS by Novartis Pharmaceuticals. It was licensed by the European Medicines Agency (EMA) on Monday 20 January 2020.

Current phase of trial: Stage 3

Type of MS: Secondary progressive MS

About siponimod